pharma · Acute Myeloid Leukemias · Breast Cancer
Syndax Pharmaceuticals
Syndax Pharmaceuticals is a pharma organization headquartered in New York, USA. Primary therapeutic focus areas include Acute Myeloid Leukemias, Breast Cancer, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemi
730 3rd Ave, Floor 9, New York, NY 10017, US HQ
325 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 730 3rd Ave, Floor 9, New York, NY 10017, US
- Employees
- 325
- Programs
- 47
- Drugs
- 29
- Patents
- 6
Revumenib
Phase 1 · small molecule · Blinatumomab
Revumenib for Blinatumomab is a Phase 1 program (small_molecule) at Syndax Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code 2025-0932
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Syndax Pharmaceuticals
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Blinatumomab
- Status
- active
- Trials
- 1